Regeneron to Report Third Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2016

TARRYTOWN, N.Y., Oct. 7, 2016

Conference Call Information
To access this call, dial (888) 771-4371 (U.S.) or (847) 585-4405 (International).  A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at www.regeneron.com.  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days. 

About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma, atopic dermatitis, pain, oncology, and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:
Investor Relations	Corporate Communications ARIVA.DE Börsen-Geflüster Werbung Weiter abwärts? Kurzfristig positionieren in Regeneron Pharmaceuticals MB9Z7H Ask: 1,14 Hebel: 18,11 mit starkem Hebel Zum Produkt MB82H5 Ask: 2,22 Hebel: 5,32 mit moderatem Hebel Zum Produkt Morgan Stanley Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie hier: MB9Z7H,MB82H5,. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen. Kurse Regeneron Pharmaceuticals 884,18 $ -0,73%
Manisha Narasimhan, Ph.D.	Hala Mirza
914.847.5126	914.847.3422
manisha.narasimhan@regeneron.com	hala.mirza@regeneron.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/regeneron-to-report-third-quarter-2016-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-4-2016-300340914.html

SOURCE Regeneron Pharmaceuticals, Inc.